Project Grant R01AG101938
- The National Institute on Aging awarded The University of Texas Southwestern Medical Center $127,493 on August 1, 2026, under the Aging Research program (CFDA 93.866) to investigate associations between midlife hypertension and brain structure and function changes, and to assess the impact of high-intensity interval training on brain outcomes in middle-aged adults with elevated blood pressure. The project combines retrospective longitudinal analysis with a proof-of-concept randomized...
- The National Institute on Aging awarded the University of Texas Health Science Center at Houston $429,000 on July 1, 2026, under the Aging Research program (CFDA 93.866) to investigate endothelial senescence intervention in limb muscle ischemia using exercise mimetics. The research will measure the effect of exercise mimesis on preventing or reversing muscle decline associated with peripheral arterial disease in aging populations. The project employs unique transgenic mouse lines, including...
- The National Institute on Aging awarded the University of Texas at Austin $650,447 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop a profile-based framework for matching transitional care services to distinct patient-caregiver groups among persons living with dementia (PLWDs). The award funds research to identify patient-caregiver profiles and co-develop provider and system implementation tools that enable tailored, evidence-based transitional care delivery across...
- The National Institute on Aging awarded The University of Chicago $597,239 on September 1, 2026, under the Aging Research program (CFDA 93.866) to support investigation of inpatient rehabilitation facility (IRF) utilization and outcomes for older adult patients with and without Alzheimer's disease or other dementias (ADRD). The research examines comparative value and appropriateness of care delivery across post-acute care settings, specifically comparing higher-cost IRF care—which provides acute...
- The National Institute on Aging, within the Department of Health and Human Services, awarded Duke University $680,818 on February 1, 2026, under the Aging Research program (CFDA 93.866) to conduct the INFUSE-HFPEF study, a double-blind, placebo-controlled randomized clinical trial evaluating intravenous iron supplementation in 300 ambulatory older patients with heart failure with preserved ejection fraction and iron deficiency. The study addresses a critical evidence gap: while intravenous...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded $437,250 to the University of Texas at Dallas on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate affective forecasting as a strategy for reducing temporal discounting across adulthood. The research addresses a critical gap in interventions for temporal discounting—the tendency to devalue delayed rewards in favor of immediate ones—which has serious implications for health...
- The National Institute on Aging awarded Visiting Nurse Service of New York $1,271,742 on September 15, 2025, under the Aging Research program (CFDA 93.866) to conduct a Stage II trial expanding the Virtual Caregiver Coach for You (ViCCY) intervention to caregivers of home health care patients with concurrent heart failure and cognitive impairment. The project enrolls 254 caregivers supporting patients with heart failure and cognitive impairment from home health care in New York City, plus at...
- The National Institute on Aging awarded Drexel University $1,306,728 under the Aging Research program (CFDA 93.866) on August 1, 2026, to conduct a longitudinal, multi-site study examining how individual lifestyle, social circumstances, and neighborhood-level factors influence physical functioning trajectories in older adults across population subgroups and U.S. regions. The research leverages over 30 years of longitudinal data from the Multi-Ethnic Study of Atherosclerosis (MESA) cohort and...
- The National Institute on Aging awarded Healthpartners Institute $1.489 million on July 1, 2026, under the Aging Research program (CFDA 93.866) to conduct an optimization trial of MAP TO HEALTH, a digital intervention designed to increase physical activity in midlife adults. The award extends through June 30, 2031. The project develops and tests a meaning- and theory-based digital behavior change intervention that delivers personalized, timely messages reminding users of their personal reasons...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Trustees of Boston University totaling $501,631 will support a study to evaluate how proteomic signatures of frailty respond to a physical rehabilitation intervention in older adults with heart failure with preserved ejection fraction (HFpEF). The key objectives are to: 1) Identify how the circulating proteome changes with physical rehabilitation in the REHAB-HF trial and how these changes relate to...
The National Institute on Aging awarded The University of Texas Southwestern Medical Center $799,870 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a randomized controlled trial testing a multi-dimensional tailored telehealth intervention for heart failure with preserved ejection fraction in older adults. The intervention integrates physical rehabilitation targeting strength, balance, mobility, and endurance with health coaching addressing emotional regulation and social engagement, designed to treat modifiable health deficits including depression, anxiety, and loneliness in this population. The study will enroll 366 participants across four arms: physical rehabilitation only, health coaching only, combined physical rehabilitation and health coaching, and attention control. Dual primary endpoints measured at 180 days are health-related quality of life (Kansas City Cardiomyopathy Questionnaire) and physical function (Short Physical Performance Battery). Secondary endpoints include all-cause mortality and total hospitalization composites and additional geriatric conditions. The award will also evaluate implementation factors across multiple stakeholder levels concurrent with effectiveness assessment in a Type 1 hybrid effectiveness-implementation design. Work is performed in Dallas, Texas. The period of performance runs from September 1, 2026, through August 31, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $799.9k | 8/21/26 |